Fortress Biotech

206 articles with Fortress Biotech

• Fortress Biotech to Participate in Two March 2023 Investor Conferences

  3/7/2023

  Fortress Biotech, Inc. today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in two investor conferences in March 2023.

• Helocyte, Inc. Announces Positive Data from Stem Cell Transplant Donor Vaccination Trial to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

  2/16/2023

  Helocyte, Inc. announced that data from a Phase 1 pilot trial evaluating the potential safety, immunological response and efficacy of the cytomegalovirus vaccine Triplex to enhance CMV protective immunity in immunosuppressed recipients of allogeneic hematopoietic cell transplants will be presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, taking place February 15-19, 2023, in Orlando, Florida.

• Study Published in American Journal of Hematology Demonstrates First Reported Evidence of Safe & Successful Boosting of Cytomegalovirus Vaccine-Specific T Cell Immunity in a Stem Cell Transplant Recipient Via Vaccination of a Donor with Triplex

  2/15/2023

  Helocyte, Inc. announced that data from a Phase 1 pilot study published in the American Journal of Hematology demonstrated the feasibility, safety, immunological response and potential efficacy associated with vaccination of a hematopoietic cell transplant donor with the cytomegalovirus vaccine Triplex to enhance protective CMV-specific T cells in immunosuppressed recipients of allogeneic HCT.

• Fortress Biotech Appoints Lucy Lu, M.D., to its Board of Directors

  12/19/2022

  Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Lucy Lu, M.D., has been appointed to its Board of Directors.

• Urica Therapeutics Expands Exclusive License Agreement with Fuji Yakuhin Co. Ltd. to Develop Dotinurad in Additional Territories Including Turkey and the Middle East and North Africa

  12/14/2022

  Urica Therapeutics, Inc., a Fortress Biotech, Inc. subsidiary company focused on the development and commercialization of pharmaceutical products to treat gout and other conditions associated with hyperuricemia, announced that the Company has expanded its exclusive license agreement with Fuji Yakuhin Co. Ltd. for the development of dotinurad to include the Middle East and North Africa and Turkey territories.

• Fortress Biotech to Participate in Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference

  12/6/2022

  Fortress Biotech, Inc. today announced that Fortress will participate in one-on-one meetings at the Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference, which is being held on Thursday, December 8, 2022.

• Fortress Biotech Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

  11/14/2022

  Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced financial results and recent corporate highlights for the third quarter ended September 30, 2022.

• Fortress Biotech Announces Timing of Regular Monthly Dividend for October, November and December 2022 for its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

  10/5/2022

  Fortress Biotech, Inc. today announced its board of directors has declared the regular monthly dividend of $0.1953125 per share of the Company’s 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock.

• Urica Therapeutics Appoints Seasoned Biotech Executive Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer

  10/3/2022

  Urica Therapeutics, Inc. today announced the appointments of Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer and Vibeke Strand, M.D., MACR, FACP, Adjunct Clinical Professor, Division of Immunology/Rheumatology, Stanford University, to its Board of Directors.

• Fortress Biotech Subsidiary Helocyte Announces Grant that Could Provide Over $20 Million from National Institute of Allergy and Infectious Diseases for Phase 2 Study of Triplex

  8/11/2022

  Fortress Biotech, Inc. today announced that Triplex, a cytomegalovirus (“CMV”) vaccine being developed by its subsidiary Helocyte, Inc. (“Helocyte”), received a grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (“NIAID/NIH”) that could provide over $20 million in non-dilutive funding.

• Fortress Biotech Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

  8/11/2022

  Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced financial results and recent corporate highlights for the second quarter ended June 30, 2022.

• Fortress Biotech Appoints David Jin as Chief Financial Officer

  7/22/2022

  Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress” or the “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced the appointment of David Jin as Chief Financial Officer effective August 16, 2022.

• Fortress Biotech Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Dotinurad for the Treatment of Gout in the United States

  5/31/2022

  Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), today announced that its subsidiary company, UR-1 Therapeutics, Inc. (“UR-1”), dosed the first patient in a Phase 1 clinical trial evaluating Dotinurad for the treatment of gout in the United States.

• Fortress Biotech to Participate in Two Upcoming May 2022 Investor Conferences

  5/18/2022

  Fortress Biotech, Inc. announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in two investor conferences in May 2022.

• Fortress Biotech Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

  5/12/2022

  Fortress Biotech, Inc. announced financial results and recent corporate highlights for the first quarter ended March 31, 2022.

• Fortress Biotech to Present at the 21st Annual Needham Virtual Healthcare Conference

  4/7/2022

  Fortress Biotech, Inc. today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate update at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022, at 1:30 p.m.

• Fortress Biotech Announces Virtual Two-Day R&D Summit Hosted by B. Riley Securities on Tuesday, April 5 and Wednesday, April 6, 2022

  4/1/2022

  Fortress Biotech, Inc. today announced a two-day summit hosted by the B. Riley Securities’ Healthcare Equity Research team, that will feature multiple programs from Fortress’ diversified pipeline.

• Fortress Biotech Reports Record 2021 Financial Results and Recent Corporate Highlights

  3/28/2022

  Fortress Biotech, Inc. today announced financial results and recent corporate highlights for the full-year ended December 31, 2021.

• Fortress Biotech to Participate in Three March 2022 Investor Conferences

  3/9/2022

  Fortress Biotech, Inc. announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in three investor conferences in March 2022.

• Fortress Biotech Announces Virtual Two-Day Corporate Access Summit Hosted by B. Riley Securities on Tuesday, April 5 and Wednesday, April 6, 2022

  3/3/2022

  Fortress Biotech, Inc. today announced a two-day summit hosted by the B. Riley Securities’ Healthcare Equity Research team, that will feature multiple programs from Fortress’ diversified pipeline.